Tegoprubart

Tegoprubart
Monoclonal antibody
Type?
Clinical data
Other namesAT-1501
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Tegoprubart (AT-1501) is an experimental humanized monoclonal antibody that inhibits CD40L. It is developed for ALS[1] and transplant rejection.[2][3][4][5]

Eledon Pharmaceuticals

In March 2026, clinical data presented at the Advanced Technologies and Treatments for Diabetes (ATTD) conference demonstrated that tegoprubart, a monoclonal antibody inhibiting the CD40 ligand, enabled 100% insulin independence in ten evaluable patients following allogeneic islet transplantation. The pilot study, conducted at the University of Chicago Medicine, utilized tegoprubart as part of a calcineurin inhibitor-free regimen, resulting in a mean HbA1c of 5.35% without evidence of nephrotoxicity or neurotoxicity typically associated with standard immunosuppressants.[6]

References

  1. ↑ Meglio, Marco. "Tegoprubart Demonstrates Safety, Target Engagement of ALS Markers in Phase 2 Study." Neurology Times, 3 Nov. 2022, p. NA. Gale Academic OneFile, link.gale.com/apps/doc/A762611032/AONE?u=anon~b1a7e306&sid=googleScholar&xid=733a3e0e. Accessed 4 Dec. 2023.
  2. ↑ Gendron, Tania F.; Petrucelli, Leonard (8 November 2023). "Immunological drivers of amyotrophic lateral sclerosis". Science Translational Medicine. 15 (721) eadj9332. doi:10.1126/scitranslmed.adj9332. PMID 37939160. S2CID 265051444.
  3. ↑ Singh, Avneesh K.; Goerlich, Corbin E.; Zhang, Tianshu; Lewis, Billeta G.T.; Hershfeld, Alena; Mohiuddin, Muhammad M. (July 2023). "CD40-CD40L Blockade: Update on Novel Investigational Therapeutics for Transplantation". Transplantation. 107 (7): 1472–1481. doi:10.1097/TP.0000000000004469. PMC 10287837. PMID 36584382.
  4. ↑ Anwar, Imran J.; Berman, Dora M.; DeLaura, Isabel; Gao, Qimeng; Willman, Melissa A.; Miller, Allison; Gill, Alan; Gill, Cindy; Perrin, Steve; Ricordi, Camillo; Ruiz, Philip; Song, Mingqing; Ladowski, Joseph M.; Kirk, Allan D.; Kenyon, Norma S. (30 August 2023). "The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates". Science Translational Medicine. 15 (711) eadf6376. doi:10.1126/scitranslmed.adf6376. PMC 10990482. PMID 37647390. S2CID 261340684.
  5. ↑ Gill, John; Coates, Patrick; Tchervenkov, Jean; Bornstein, Jeffrey; Harden, Paul; Kadatz, Matthew; Witkowski, Piotr (October 2023). "318.5: Emerging data from a study of tegoprubart for the prevention of rejection in kidney transplant recipients: Implications for a similar study in islet cell transplantation". Transplantation. 107 (10S2): 124. doi:10.1097/01.tp.0000994460.57811.03.
  6. ↑ Brooks, Abigail (March 16, 2026). "Tegoprubart Enables Insulin Independence in Type 1 Diabetes Islet Transplant Study". HCPLive.